BCL11B altered ETP-ALL is associated with FLT3 alterations [14, 17, 87] indicating first or second generation FLT3 kinase inhibitors such as sorafenib or quizartinib as potential therapeutics in this subtype when a FLT3 alteration is present [25, 88]. Here, FLT3 is linked to acute lymphoblastic leukemia.